IRIS
BUTTARI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.150
AS - Asia 2.914
EU - Europa 2.166
SA - Sud America 417
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 9
Totale 19.711
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.083
SG - Singapore 1.343
IT - Italia 559
CN - Cina 480
BR - Brasile 361
RU - Federazione Russa 352
HK - Hong Kong 271
VN - Vietnam 255
KR - Corea 243
IE - Irlanda 226
DE - Germania 208
FR - Francia 139
UA - Ucraina 137
GB - Regno Unito 120
JP - Giappone 87
FI - Finlandia 80
PL - Polonia 76
NL - Olanda 57
SE - Svezia 54
CA - Canada 43
IN - India 40
AR - Argentina 24
AT - Austria 24
ID - Indonesia 24
BE - Belgio 23
IQ - Iraq 22
TR - Turchia 21
CZ - Repubblica Ceca 20
BD - Bangladesh 19
ZA - Sudafrica 19
ES - Italia 17
UZ - Uzbekistan 16
PH - Filippine 12
RO - Romania 11
PK - Pakistan 10
RS - Serbia 9
SA - Arabia Saudita 9
CH - Svizzera 8
CL - Cile 8
CO - Colombia 8
EU - Europa 8
GR - Grecia 8
LT - Lituania 8
MA - Marocco 8
MX - Messico 8
AU - Australia 6
DK - Danimarca 6
IR - Iran 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
EC - Ecuador 5
HR - Croazia 5
MY - Malesia 5
IL - Israele 4
KE - Kenya 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NO - Norvegia 4
OM - Oman 4
TH - Thailandia 4
BN - Brunei Darussalam 3
CY - Cipro 3
DM - Dominica 3
EG - Egitto 3
JM - Giamaica 3
PT - Portogallo 3
TN - Tunisia 3
TW - Taiwan 3
AZ - Azerbaigian 2
CG - Congo 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HN - Honduras 2
JO - Giordania 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NG - Nigeria 2
QA - Qatar 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MU - Mauritius 1
NP - Nepal 1
NR - Nauru 1
Totale 19.705
Salva come PNG Salva come JPEG
Città #
Wilmington 3.414
Houston 3.140
Woodbridge 2.637
Singapore 787
Chandler 527
Fairfield 486
Ashburn 351
San Jose 302
Ann Arbor 279
Hong Kong 249
Dublin 199
Seattle 193
New York 182
Beijing 178
Dallas 175
Cambridge 161
Rome 160
The Dalles 154
Medford 129
Santa Clara 103
Jacksonville 91
Ho Chi Minh City 88
Los Angeles 87
Council Bluffs 84
Tokyo 81
Dearborn 79
Lawrence 62
Hanoi 58
Lauterbourg 58
Buffalo 54
Munich 54
Kraków 51
São Paulo 49
Moscow 44
Zhengzhou 43
Milan 33
London 29
Lappeenranta 26
Orem 26
Chicago 25
Palo Alto 24
Brussels 23
North Bergen 23
Norwalk 23
Philadelphia 23
San Diego 23
Warsaw 22
Helsinki 21
Brooklyn 19
Redondo Beach 19
Southern 19
Columbus 18
Jakarta 18
Chennai 17
Brno 16
Frankfurt am Main 16
Seoul 16
Johannesburg 15
Menlo Park 15
Redwood City 15
Boston 14
Colorado Springs 14
Montreal 14
Naples 14
Denver 13
Roebling 13
Amsterdam 12
Arosio 12
Nanjing 12
Rio de Janeiro 12
Tampa 12
Toronto 12
Nuremberg 11
Stockholm 11
Paris 10
Belo Horizonte 9
Guangzhou 9
San Francisco 9
Ankara 8
Atlanta 8
Belgrade 8
Bologna 8
Center 8
Elk Grove Village 8
Falls Church 8
Hefei 8
Inverigo 8
Phoenix 8
Poplar 8
Salt Lake City 8
Tashkent 8
Turku 8
Vienna 8
Catania 7
Detroit 7
Haiphong 7
Hải Dương 7
Mountain View 7
Nanchang 7
Palermo 7
Totale 15.695
Salva come PNG Salva come JPEG
Nome #
Neurophysiology of synaptic functioning in multiple sclerosis 573
miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation 521
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration 515
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 515
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 503
Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis 492
Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study 483
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads 479
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 469
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis 468
Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis 462
Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53 459
CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis 458
Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances 449
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 440
Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain 431
Epstein-Barr virus genetic variants are associated with multiple sclerosis 426
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study 404
Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis 402
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis 397
Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids 396
Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems 391
Reversible hyporegenerative anemia during natalizumab treatment 388
Remodeling functional connectivity in multiple sclerosis: A challenging therapeutic approach 360
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 360
Dimethyl fumarate vs. fingolimod in multiple sclerosis: an independent, multi-centre, real world, quasi-randomized study 346
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 327
Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation 323
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 318
Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis 312
Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis 292
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 279
Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions 269
Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression 264
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 201
Prototypical proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting 193
Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons 193
MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis 174
Multiple Sclerosis: kFLC index values related to gender 173
Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis 164
Exercise protects from hippocampal inflammation and neurodegeneration in experimental autoimmune encephalomyelitis 163
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 161
Modeling Resilience to Damage in Multiple Sclerosis: Plasticity Meets Connectivity 161
Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis 155
Re-Examining the Role of TNF in MS Pathogenesis and Therapy 145
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis 137
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis 134
MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis 126
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients 124
The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis 124
A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset 121
Corrigendum: Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis 113
Cerebrospinal fluid levels of L-glutamate signal central inflammatory neurodegeneration in multiple sclerosis 112
Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis 110
Age at disease onset associates with oxidative stress, neuroinflammation, and impaired synaptic plasticity in relapsing-remitting multiple sclerosis 107
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 106
A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: implications for cladribine treatment 106
Cerebrospinal fluid, brain, and spinal cord levels of L-aspartate signal excitatory neurotransmission abnormalities in multiple sclerosis patients and experimental autoimmune encephalomyelitis mouse model 100
Interleukin-9 protects from microglia- and TNF-mediated synaptotoxicity in experimental multiple sclerosis 100
A large family with p.Arg554His mutation in ABCD1: clinical features and genotype/phenotype correlation in female carriers 99
Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients 97
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential 95
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab 95
Interleukin-1β alters hebbian synaptic plasticity in multiple sclerosis 91
Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis 90
Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective 87
The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis 87
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammation 86
Decipher non-canonical SPAST splicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 (SPG4) 84
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 84
Preventive exercise and physical rehabilitation promote long-term potentiation-like plasticity expression in patients with multiple sclerosis 81
Genetic regulation of IL-8 influences disease presentation of multiple sclerosis 80
Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis 79
Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosis 76
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 75
BACE1 influences clinical manifestations and central inflammation in relapsing remitting multiple sclerosis 75
An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis 75
Osteopontin Is Associated with Multiple Sclerosis Relapses 74
Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis 74
Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity 72
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 72
Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis 70
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study) 69
Cortical plasticity in AQP4-positive NMOSD: a transcranial magnetic stimulation study 68
Interaction between miR-142-3p and BDNF Val/Met Polymorphism Regulates Multiple Sclerosis Severity 66
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 63
Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression 58
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 54
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 50
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 47
Maresin-1 promotes neuroprotection and prevents disease progression in experimental models of multiple sclerosis through metabolic reprogramming and shaping innate and adaptive disease-associated cell types 46
IL-1β contributes to neurological disability in NMOSD AQP4 + Patients 46
New variants and genotype–phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort 44
Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis 34
Cladribine tablets in the new multiple sclerosis era 29
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled Trials 29
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 22
Totale 20.097
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.375
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.375
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021100 0 0 0 0 0 0 0 0 0 0 71 29
2021/2022689 34 29 16 40 3 127 29 34 77 88 27 185
2022/20231.287 135 115 110 198 73 278 85 63 99 13 60 58
2023/2024531 84 20 22 29 39 118 28 40 25 26 21 79
2024/20252.201 85 427 168 93 142 216 179 103 208 267 167 146
2025/20263.669 326 182 527 270 365 132 612 475 445 309 26 0
Totale 20.097